Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.
Zachary D MichelSarah F AitkenOmar D GloverLucy O AlejandroDavide RandazzoCarl DambkowskiDavid MartinMichael T CollinsMartha J SomermanEmily Y ChuPublished in: Developmental dynamics : an official publication of the American Association of Anatomists (2023)
High dose infigratinib administered to rats during early stages affects dental and craniofacial development. Changes in CTSK from infigratinib in female rats suggest FGFR roles in bone homeostasis. While dental and craniofacial disruptions are not expected at therapeutic doses, our findings confirm the importance of dental monitoring in clinical studies.